Research Library
Curated Studies & Clinical Data
A growing library of peer-reviewed studies, clinical trial data, and systematic reviews organized by compound. Every citation is linked to its primary source.
Beyond GLP-1 Agonists: Plant-Derived Bioactive Compounds as Adjunctive Strategies for Obesity Management
Nutrients, 2026;18(14)
Association of Glucagon-Like Peptide-1 Receptor Agonists With Menstrual Events in Reproductive-Aged Patients
Obstetrics and gynecology, 2026
Patterns of Use for GLP-1 Receptor Agonists in a Weight Management Cohort: A Military Health System Database Analysis of Active Duty Service Members From 2021 to 2025
Military medicine, 2026
Effect of glucagon-like peptide-1 receptor agonists on body weight and urinary albumin-to-creatinine ratio in patients with and without type 2 diabetes: A systematic review and meta-analysis
The Journal of international medical research, 2026;54(7):3000605261458641
Special Considerations When Using GLP-1 Receptor Agonists in the Treatment of Obesity and Diabetes Mellitus Type 2 in Older Adults
Advances in therapy, 2026
Pharmacological Therapy for Metabolic Dysfunction-Associated Steatotic Liver Disease in a New Era for Obesity and Metabolic Medicine: A State-of-the-Art Review
Journal of obesity & metabolic syndrome, 2026
Tirzepatide and risk of newly diagnosed aortic stenosis in patients with obesity: a multi-institutional real-world cohort study
BMC cardiovascular disorders, 2026
Efficacy and Safety of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Ventricular Arrhythmias and Cardiovascular Events: A Disease-Stratified Network Meta-Analysis
Diabetes, obesity & metabolism, 2026
Retatrutide fact check: Has a man died after taking the unapproved weight loss jab?
BMJ (Clinical research ed.), 2026;394:e100245
GLP-1 regulates osteo-adipogenic fate of BMSCs via HIF-2-AKT signaling and supports trabecular bone in glucocorticoid-induced osteoporosis
Stem cell reports, 2026;:103008
Hyperuricemia, gout and obesity: should weight management be more of a focus in gout management?
Nutrition, metabolism, and cardiovascular diseases : NMCD, 2026;:104860
Employee perceptions and experiences with tirzepatide treatment for obesity or overweight in the US: Insights from the PERCEPTIONS Survey
Obesity pillars, 2026;19:100298
Oral Health Implications of GLP-1 Receptor Agonists and Other Incretin-Based Therapies
Journal of clinical medicine, 2026;15(14)
Holistic Management of Obesity in Patients with Incidental Cancer After Unprovoked Deep Vein Thrombosis: A Cardiometabolic and Antithrombotic Framework
Cancers, 2026;18(14)
GLP-1 and MASH: When weight loss isn’t the whole story
Cell metabolism;38(7):1258-1260
Real-World vs. Randomized Trial Evidence for Incretin-Based Therapies: A Narrative Review
Journal of diabetes;18(7):e70248
Pharmacological Interventions for Weight Reduction in Patients With Schizophrenia Treated With Antipsychotics: A Systematic Review and Network Meta-Analysis
JAMA psychiatry, 2026
Disrupting the adiposopathy-inflammation loop: a translational immunometabolic framework for inflammatory disease
Journal of translational medicine, 2026
Comparative effectiveness of tirzepatide and DPP-4 inhibitors in type 2 diabetes with heart failure
Diabetes & vascular disease research, 2026;23(4):14791641261467888
Neuropsychiatric Outcomes With Tirzepatide, Semaglutide, and Other GLP-1 Receptor Agonists
Diabetes, obesity & metabolism, 2026